Related Experiment Video

Updated: Jul 18, 2026

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

[Neurohormonal blockade in patients with heart failure at discharge from hospital]

J M Casado1, E Visus, J P Recio

  • 1Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid. casadocerrada@hotmail.com

Anales De Medicina Interna (Madrid, Spain : 1984)
|December 1, 2006
PubMed

Insights

This study assessed medication adherence in 554 heart failure patients. While ACE inhibitors were common, underuse of spironolactone and beta-blockers remains a concern for heart failure treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Context:

  • Heart failure (HF) management requires optimal pharmacological treatment.
  • Therapeutic adherence is crucial for effective HF patient outcomes.
  • The ATICA study investigated adherence to guideline-recommended HF therapies.

Purpose:

  • To evaluate the degree of fulfillment of pharmacological treatment in heart failure patients.
  • To identify patterns of medication use and underutilization in a large cohort.
  • To assess adherence to neurohormonal agents in heart failure management.

Summary:

  • The ATICA pilot study included 554 heart failure patients, predominantly women with advanced age and preserved ejection fraction.
  • Data collected included demographics, medical history, and medication use, focusing on neurohormonal agents.
  • Angiotensin-converting enzyme inhibitors (ACEIs) were the most prescribed, but spironolactone and beta-blockers showed concerning underutilization despite increased prescription rates compared to other studies.

Impact:

  • Highlights significant underutilization of key heart failure medications like spironolactone and beta-blockers.
  • Provides data on adherence patterns in a large heart failure cohort, informing clinical practice.
  • Identifies areas for intervention to improve guideline-directed medical therapy fulfillment in heart failure.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.